StockNews.AI
NPCE
StockNews.AI
181 days

NeuroPace to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025

1. NeuroPace to report Q4 and FY 2024 results on March 4, 2025. 2. Management will host a conference call at 1:30 PM PT. 3. RNS System provides a personalized, real-time treatment for epilepsy. 4. Potential impact on standards of care for drug-resistant epilepsy patients.

4m saved
Insight
Article

FAQ

Why Bullish?

Positive earnings report anticipation may lift NPCE stock; similar future events enhanced market confidence.

How important is it?

Upcoming financial results crucial for providing insights on company growth and potential stock trajectory.

Why Short Term?

Earnings report will provide immediate insights; past reports have shown short-term price fluctuations.

Related Companies

NASDAQ: NPCE
February 19, 2025 16:05 ET  | Source: NeuroPace, Inc. MOUNTAIN VIEW, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter and full year of 2024 after market close on Tuesday, March 4, 2025. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at https://viavid.webcasts.com/starthere.jsp?ei=1706647&tp_key=43fdbb668b. Individuals interested in participating in the call via telephone may access the call by dialing +1-877-407-3982 and referencing Conference ID 13751530. The webcast will be archived on the company’s investor relations website at https://investors.neuropace.com/news-and-events/events and will be available for replay for at least 90 days after the event. About NeuroPace, Inc. Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders. Investor Contact:Jeremy Feffer Managing Director LifeSci Advisorsjfeffer@lifesciadvisors.com

Related News